Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 100

Sort by

Sort Order Select

Journal Articles

Pomalidomide, Dexamethasone, and Daratumumab after Lenalidomide Treatment in Relapsed Refractory Multiple Myeloma: Updated Results from an Open-Label, Multicenter, Phase 2 Trial

David S. Siegel, MD PhD, Gary J. Schiller, MD, Christy J. Samaras, DO, Michael Sebag, MD PhD FRCPC, Jesus G. Berdeja, MD, Siddhartha Ganguly, MD, Jeffrey V. Matous, MD, Kevin W Song, MD FRCPC, Christopher S. Seet, MD PhD, Mirelis Acosta-Rivera, Michael Bar, Donald P. Quick, MD, Bertrand M. Anz, III, MD, Gustavo A. Fonseca, MD, Donna E. Reece, MD, Kim Lee, Weiyuan Chung, Amit Agarwal, MD PhD, Nizar J. Bahlis, MD

Blood (2020) 136 (Supplement 1): 16–17.

https://doi.org/10.1182/blood-2020-134189

Published: 2020

Journal Articles

Daratumumab (DARA) Plus Carfilzomib, Pomalidomide, Dexamethasone (KPd) in Lenalidomide Refractory Multiple Myeloma (MM): A Multi-Center MMRC Study

Jagoda Jasielec, MD, Jeff Zonder, MD, Benjamin A Derman, MD, Donna E. Reece, MD, Craig E. Cole, MD, Jesus G. Berdeja, MD, Brittany Wolfe, Sarah Major, Kathryn M. Tinari, Andrew Stefka, MS, Fabrizio Fazzi, Megan Whelan, Christine Gleason, Amanda McIver, Evangelia Andreatos, Bernadette M. Libao, Daniel Juergens, Kent Griffith, Andrzej Jakubowiak, MD PhD

Blood (2020) 136 (Supplement 1): 50.

https://doi.org/10.1182/blood-2020-141029

Published: 2020

Journal Articles

Is Tandem ASCT Needed in MM Patients with High Risk Cytogenetics in the Era of Maintenance Therapy? Results from the Canadian Myeloma Research Group (CMRG) Database

Peter Duggan, MD FRCPC, Donna E. Reece, MD, Kevin Song, MD, Victor Jimenez-Zepeda, MD, Arleigh McCurdy, MD BSc, Martha L Louzada, MDMSc, Hira S Mian, MD, Michael Sebag, MD PhD FRCPC, Darrell J White, MD, Julie Stakiw, MD, Richard Leblanc, MD FRCPC, Esther Masih-Khan, Eshetu G Atenafu, M.Sc., P.Stat, Rami Kotb, MD, Muhammad Aslam, MD, Anthony Reiman, MD, Engin Gul, BS, MBA, Christopher P. Venner, MD

Blood (2020) 136 (Supplement 1): 18–19.

https://doi.org/10.1182/blood-2020-139689

Published: 2020

Journal Articles

Sequential Use of Carfilzomib and Pomalidomide in Relapsed Multiple Myeloma: A Multi-Institutional Report from the Canadian Myeloma Research Group (CMRG) Database

Arleigh McCurdy, MD BSc, Christopher P. Venner, MD, Martha L Louzada, MDMSc, Richard LeBlanc, MD FRCPC, Michael Sebag, MD PhD FRCPC, Kevin W Song, MD FRCPC, Victor Jimenez-Zepeda, MD, Rami Kotb, MD, Esther Masih-Khan, PhD, Eshetu G Atenafu, MSc, P.Stat, Hira S Mian, MD, Darrell J White, MD, Julie Stakiw, MD, Muhammad Aslam, MD, Anthony Reiman, MD, Engin Gul, BSc, Donna E. Reece, MD

Blood (2020) 136 (Supplement 1): 5–7.

https://doi.org/10.1182/blood-2020-142800

Published: 2020

Journal Articles

Efficacy of Daratumumab Containing Regimens Post Lenalidomide Maintenance in Transplant Eligible Patients: Real-World Experience from the Canadian Myeloma Research Group Database

Hira S Mian, MD, Christine Eisfeld, Christopher P. Venner, MD, Victor Jimenez-Zepeda, MD, Cyrus Khandanpour, MD, Arleigh McCurdy, MD BSc, Michael Sebag, MD PhD FRCPC, Kevin W Song, MD FRCPC, Richard Leblanc, MD FRCPC, Esther Masih-Khan, PhD, Eshetu G Atenafu, MSc, P.Stat, Darrell J White, MD, Julie Stakiw, MD, Anthony Reiman, MD, Martha L Louzada, MDMSc, Muhammad Aslam, MD, Rami Kotb, MD, Engin Gul, BS, MBA, Donna E. Reece, MD

Blood (2020) 136 (Supplement 1): 26–27.

https://doi.org/10.1182/blood-2020-133372

Published: 2020

Journal Articles

Idecabtagene Vicleucel (ide-cel, bb2121) in Relapsed and Refractory Multiple Myeloma: Analyses of High-Risk Subgroups in the KarMMa Study

Noopur S. Raje, MD, David S. Siegel, MD PhD, Sundar Jagannath, MD, Sagar Lonial, MD FACP, Nikhil C. Munshi, MD, Philippe Moreau, MD, Hartmut Goldschmidt, MD, Michele Cavo, Anna Truppel-Hartmann, MD, Everton Rowe, PhD, Liping Huang, PhD, Amit Agarwal, MD PhD, Julie Wang, PharmD, PhD, Timothy B. Campbell, MD PhD, Jesus F. San-Miguel, MD PhD, Donna E. Reece, MD

Blood (2020) 136 (Supplement 1): 37–38.

https://doi.org/10.1182/blood-2020-134319

Published: 2020

Journal Articles

A Randomized Phase II, Open Label, Study of Daratumumab, Weekly Low-Dose Oral Dexamethasone and Cyclophosphamide with or without Pomalidomide in Patients with Relapsed and Refractory Multiple Myeloma

Michael Sebag, MD PhD FRCPC, Nizar J. Bahlis, MD, Christopher P. Venner, MD, Arleigh McCurdy, MD BSc, C. Tom Kouroukis, MDMSc,FRCPC, Jesse Shustik, MD, Rami Kotb, MD, Darrell J White, MD, Julie Stakiw, MD, Nicole B. Laferriere, MD PhD, Anthony Reiman, MD, Fernando Camacho, PhD, Molei Fu, Engin Gul, BSc, Donna E. Reece, MD

Blood (2020) 136 (Supplement 1): 6.

https://doi.org/10.1182/blood-2020-141087

Published: 2020

Journal Articles

Overall and Progression Free Survival from the Mcrn-003/Myx.1 Trial: A Single Arm Phase II Study of High-Dose Weekly Carfilzomib Plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed Multiple Myeloma

Christopher P Venner, MD, Richard Leblanc, MDFRCPC, Irwindeep Sandhu, MDFRCPC, Darrell J White, MD, Andrew Belch, MD, Donna E Reece, MD, Christine I Chen, MD, Sean Dolan, MD, Marc Lalancette, MD FRCP, Martha L Louzada, MDMSc, Andrea Kew, MDFRCP(C), Arleigh McCurdy, MD, Tony Reiman, MD, Max Sherry, Gail T. McDonald, Bethany Elaine Monteith, MD, Engin Gul, BS, MBA, Bingshu E. Chen, Annette E. Hay

Blood (2019) 134 (Supplement_1): 1871.

https://doi.org/10.1182/blood-2019-122637

Published: 2019

Journal Articles

Outcomes of Patients with t(11;14) Multiple Myeloma: An International Myeloma Working Group Multicenter Study

Blood (2019) 134 (Supplement_1): 3066.

https://doi.org/10.1182/blood-2019-126867

Published: 2019

Journal Articles

Quality of Life and Caregiver Burden in Patients and Their Caregivers Undergoing Outpatient Autologous Stem Cell Transplantation Compared to Inpatient Transplantation

Vinita Dhir, BSc, Lara Zibdawi, Harminder K Paul, MSc, Osvaldo Espin-Garcia, PhD, Christine I Chen, MD, Michael Crump, MD FRCPC, Robert Kridel, MDMPH,PhD, Vishal Kukreti, MD, John Kuruvilla, MD, Donna E Reece, MD, Rodger E Tiedemann, MBChB, PhD, Suzanne Trudel, MD, Anca Prica, MD

Blood (2019) 134 (Supplement_1): 62.

https://doi.org/10.1182/blood-2019-131281

Published: 2019

Journal Articles

Targeted Mass Spectrometry-Based Serum M-Protein Monitoring for Early Relapse Detection

Zac McDonald, PhD, Mariya Liyasova, PhD, Paul Taylor, Xin Xu, Kathleen Gorospe, Chenyu Yao, Qixin Liu, Liqiang Yang, PhD, Bin Ma, PhD, Jesus Piza, MD, Donna E Reece, MD, Suzanne Trudel, MD

Blood (2019) 134 (Supplement_1): 4347.

https://doi.org/10.1182/blood-2019-130251

Published: 2019

Journal Articles

Bortezomib-Based Induction, Augmented Conditioning with Busulfan and Melphalan + ASCT and Lenalidomide Maintenance for Newly Diagnosed Multiple Myeloma: Long-Term Results of the National Canadian Mcrn-001 Study

Donna E Reece, MD, Giovanni Piza Rodriguez, MD, Mariela A Pantoja, PhD MSc, Darrell J White, MD, Christopher P Venner, MD, Julie Stakiw, MD, Michael Sebag, MD PhD, Terrance Comeau, MD, Kevin Song, MD, Jean Roy, MD, Martha L Louzada, MDMSc, Arleigh McCurdy, MD, Vishal Kukreti, MD, Suzanne Trudel, MD, Anca Prica, MD, Rodger E Tiedemann, MBChB, PhD, Harminder K Paul, MSc, Christine I Chen, MD

Blood (2019) 134 (Supplement_1): 4570.

https://doi.org/10.1182/blood-2019-129357

Published: 2019

Journal Articles

Salvage Autologous Stem Cell Transplant in Relapsed Myeloma Patients in the Era of Modern Treatment: Is There a Role?

Sahar Khan, Eshetu G Atenafu, M.Sc., P.Stat, Christine I Chen, MD, Esther Masih-Khan, PhD, Lavinia Aileen Jeyanathan, Anca Prica, MD, Donna E Reece, MD, Rodger E Tiedemann, MBChB, PhD, Suzanne Trudel, MD, Vishal Kukreti, MD

Blood (2019) 134 (Supplement_1): 5704.

https://doi.org/10.1182/blood-2019-130733

Published: 2019

Journal Articles

A Randomized Phase II, Open Label, Study of Daratumumab, Weekly Low-Dose Oral Dexamethasone and Cyclophosphamide with or without Pomalidomide in Patients with Relapsed and Refractory Multiple Myeloma

Michael Sebag, MD PhD, Nizar Bahlis, MD, Christopher P. Venner, Arleigh McCurdy, MD, C. Tom Kouroukis, MDMSc,FRCPC, Jesse Shustik, MD, Darrell J White, MD, Rami Kotb, MD, Julie Stakiw, MD, Nicole B. Laferriere, MD PhD, Tony Reiman, MD, Fernando Camacho, Julia Dobbin, Molei Fu, Engin Gul, BS, MBA, Donna E Reece, MD

Blood (2019) 134 (Supplement_1): 3121.

https://doi.org/10.1182/blood-2019-124457

Published: 2019

Journal Articles

Treatment of Multiple Myeloma Patients Progressing on Lenalidomide-Based Regimens

Donna E Reece, MD, Esther Masih-Khan, PhD, Eshetu G Atenafu, MSc, P.Stat, Victor Jimenez-Zepeda, MD, Arleigh McCurdy, MD, Kevin Song, MD, Michael Sebag, MD PhD, Richard Leblanc, MDFRCPC, Martha L Louzada, MDMSc, Darrell J White, MD, Julie Stakiw, MD, Tony Reiman, MD, Rami Kotb, MD, Muhammad Aslam, MD, Engin Gul, BS, MBA, Christopher P Venner, MD

Blood (2019) 134 (Supplement_1): 1886.

https://doi.org/10.1182/blood-2019-125479

Published: 2019

Journal Articles

Treatment of Myeloma Patients Progressing on Lenalidomide-Based Maintenance after ASCT Performed As Part of 1 st , 2 nd or 3 rd Line Therapy: Real-World Results from the National Myeloma Canada Research Network (MCRN) Database

Donna E Reece, MD, Esther Masih-Khan, PhD, Eshetu G Atenafu, MSc, P.Stat, Victor Jimenez-Zepeda, MD, Arleigh McCurdy, MD, Kevin Song, MD, Richard Leblanc, MDFRCPC, Michael Sebag, MD PhD, Darrell J White, MD, Hannah Cherniawsky, BSc,MD, Tony Reiman, MD, Julie Stakiw, MD, Martha L Louzada, MDMSc, Rami Kotb, MD, Muhammad Aslam, MD, Engin Gul, BS, MBA, Christopher P Venner, MD

Blood (2019) 134 (Supplement_1): 3173.

https://doi.org/10.1182/blood-2019-125810

Published: 2019

Journal Articles

Real-World Outcomes with Bortezomib-Containing Regimens and Lenalidomide Plus Dexamethasone for the Treatment of Transplant Ineligible MM Patients: A Multi-Institutional Report from the National Myeloma Canada Research Network (MCRN) Database

Victor Jimenez-Zepeda, MD, Donna E Reece, MD, McCurdy R Arleigh, MD MHA, FRCPC, Esther Masih-Khan, PhD, Eshetu G Atenafu, MSc, P.Stat, Michael Sebag, MD PhD, Julie Stakiw, MD FRCPC, Kevin Song, MD, Richard Leblanc, MDFRCPC, Tony Reiman, MD, Martha L Louzada, MD, Rami Kotb, MD, Engin Gul, BSc, Christopher P. Venner, MD FRCPC

Blood (2018) 132 (Supplement 1): 2008.

https://doi.org/10.1182/blood-2018-99-117363

Published: 2018

Journal Articles

Infectious Complications in the Outpatient and Inpatient Autologous Stem Cell Transplantation Setting for Patients with Multiple Myeloma. Princess Margaret Cancer Center Experience

Anna Nikonova, MD, Christina Zeglinski, NP, Shahid Husain, MD MS, Miranda So, PharmD, Eshetu G Atenafu, M.Sc., P.Stat, Donna E Reece, MD, Suzanne Trudel, MD FRCP(C), Vishal Kukreti, MD, Rodger E. Tiedemann, Anca Prica, MD, Norman Anthony Franke, MD, Jane Huynh, NP, Leeping Tao, NP, Christine I Chen, MD

Blood (2018) 132 (Supplement 1): 4614.

https://doi.org/10.1182/blood-2018-99-118775

Published: 2018

Journal Articles

MCRN ¯ 003/MYX · 1: A Single Arm Phase II Study of High-Dose Weekly Carfilzomib Plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed Multiple Myeloma after 1-3 Prior Therapies

Christopher P. Venner, MD FRCPC, Richard Leblanc, MDFRCPC, Irwindeep Sandhu, MDFRCPC, Darrell J. White, MD, Andrew R Belch, MD, Donna E Reece, MD, Christine I Chen, MD, Sean Dolan, MD, Andrea Kew, MDFRCP(C), Marc Lalancette, MD FRCP, Martha L Louzada, MD, Arleigh McCurdy, MD BSc, Gail T. McDonald, Tony Reiman, MD, Laura Rodriguez, Lois E. Shepherd, Engin Gul, BSc, Bingshu E. Chen, Annette E Hay

Blood (2018) 132 (Supplement 1): 1984.

https://doi.org/10.1182/blood-2018-99-117824

Published: 2018

Journal Articles

Patient, Disease and Treatment Characteristics of Long-Term Survivors of Multiple Myeloma

Michael Kennah, MD, Nastaran Noroozi, MD FRCPC, Esther Masih-Khan, PhD, Tony Panzarella, M.Sc., P.Stat., Donna E Reece, MD FRCPC, Suzanne Trudel, MD, Vishal Kukreti, MD FRCPC, Rodger Tiedemann, MBChB, PhD, Christine I. Chen, MD MD FRCPC

Blood (2014) 124 (21): 2019.

https://doi.org/10.1182/blood.V124.21.2019.2019

Published: 2014

NARROW

Pomalidomide, Dexamethasone, and Daratumumab after Lenalidomide Treatment in Relapsed Refractory Multiple Myeloma: Updated Results from an Open-Label, Multicenter, Phase 2 Trial

Daratumumab (DARA) Plus Carfilzomib, Pomalidomide, Dexamethasone (KPd) in Lenalidomide Refractory Multiple Myeloma (MM): A Multi-Center MMRC Study

Is Tandem ASCT Needed in MM Patients with High Risk Cytogenetics in the Era of Maintenance Therapy? Results from the Canadian Myeloma Research Group (CMRG) Database

Sequential Use of Carfilzomib and Pomalidomide in Relapsed Multiple Myeloma: A Multi-Institutional Report from the Canadian Myeloma Research Group (CMRG) Database

Efficacy of Daratumumab Containing Regimens Post Lenalidomide Maintenance in Transplant Eligible Patients: Real-World Experience from the Canadian Myeloma Research Group Database

Idecabtagene Vicleucel (ide-cel, bb2121) in Relapsed and Refractory Multiple Myeloma: Analyses of High-Risk Subgroups in the KarMMa Study

A Randomized Phase II, Open Label, Study of Daratumumab, Weekly Low-Dose Oral Dexamethasone and Cyclophosphamide with or without Pomalidomide in Patients with Relapsed and Refractory Multiple Myeloma

Overall and Progression Free Survival from the Mcrn-003/Myx.1 Trial: A Single Arm Phase II Study of High-Dose Weekly Carfilzomib Plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed Multiple Myeloma

Outcomes of Patients with t(11;14) Multiple Myeloma: An International Myeloma Working Group Multicenter Study

Quality of Life and Caregiver Burden in Patients and Their Caregivers Undergoing Outpatient Autologous Stem Cell Transplantation Compared to Inpatient Transplantation

Targeted Mass Spectrometry-Based Serum M-Protein Monitoring for Early Relapse Detection

Bortezomib-Based Induction, Augmented Conditioning with Busulfan and Melphalan + ASCT and Lenalidomide Maintenance for Newly Diagnosed Multiple Myeloma: Long-Term Results of the National Canadian Mcrn-001 Study

Salvage Autologous Stem Cell Transplant in Relapsed Myeloma Patients in the Era of Modern Treatment: Is There a Role?

A Randomized Phase II, Open Label, Study of Daratumumab, Weekly Low-Dose Oral Dexamethasone and Cyclophosphamide with or without Pomalidomide in Patients with Relapsed and Refractory Multiple Myeloma

Treatment of Multiple Myeloma Patients Progressing on Lenalidomide-Based Regimens

Treatment of Myeloma Patients Progressing on Lenalidomide-Based Maintenance after ASCT Performed As Part of 1 st , 2 nd or 3 rd Line Therapy: Real-World Results from the National Myeloma Canada Research Network (MCRN) Database

Real-World Outcomes with Bortezomib-Containing Regimens and Lenalidomide Plus Dexamethasone for the Treatment of Transplant Ineligible MM Patients: A Multi-Institutional Report from the National Myeloma Canada Research Network (MCRN) Database

Infectious Complications in the Outpatient and Inpatient Autologous Stem Cell Transplantation Setting for Patients with Multiple Myeloma. Princess Margaret Cancer Center Experience

MCRN ¯ 003/MYX · 1: A Single Arm Phase II Study of High-Dose Weekly Carfilzomib Plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed Multiple Myeloma after 1-3 Prior Therapies

Patient, Disease and Treatment Characteristics of Long-Term Survivors of Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only